Mrs Stephanie Frances Senogles, MSW, LCSW | |
522 George St., Suite B, Depere, WI 54115 | |
(920) 639-3907 | |
Not Available |
Full Name | Mrs Stephanie Frances Senogles |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 522 George St., Depere, Wisconsin |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1326292905 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 6655-123 (Wisconsin) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Stephanie Frances Senogles, MSW, LCSW 522 George St., Suite B, De Pere, WI 54115 Ph: (920) 639-3907 | Mrs Stephanie Frances Senogles, MSW, LCSW 522 George St., Suite B, Depere, WI 54115 Ph: (920) 639-3907 |
News Archive
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $21.0 million of shares of its Series 7 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to four institutional investors.
Illinois cancer patients no longer have to choose between costly life-saving treatments and preserving their ability to one day have their own biological children, thanks to a fertility preservation bill signed Aug. 27 by Gov. Bruce Rauner at Northwestern Medicine Prentice Women's Hospital.
A new drug called bumetanide, which is used to treat edema, shows promise in treating some symptoms of autism in young children, while not showing significant adverse effects. The study was published in January 2020 in the journal Translational Psychiatry.
It's normal for expectant parents to worry about how well their baby is developing and growing. But could a newborn's birthweight serve as a red flag for risks to mom's future health, too?
Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.
› Verified 9 days ago